|
ClostraBio offers versatile solutions for delivery of bacterial metabolites.
|
PROBIOTIC SUPPLEMENT
CLB101™ is a butyrate-producing probiotic found to be in decreased abundance in infants with food allergy THERAPEUTIC ASSET
CLB-004 treats the underlying condition in non-communicable chronic diseases of the gut, by modulating barrier function and immune response |
Non-communicable chronic diseases are associated with impaired barrier function
Due to an altered intestinal microbiome
Due to an altered intestinal microbiome
Decreased dietary fiber
|
Decreased bacterial diversity
|
Decreased short chain fatty acid (SCFA) production
|
Impaired intestinal barrier function
|
Disruption of tight junctions & mucus film covering the epithelial layer causes increased permeability of the intestinal epithelium & increased uptake of luminal or food antigens, ultimately leading to chronic inflammation.
Modern lifestyle factors, including diets low in dietary fiber, results in a loss of gut microbial diversity linked to decreased levels of key bacterial metabolites and impaired intestinal barrier function.
Iweala and Nagler, Annual Reviews Immunology 2019; Vijay and Valdes, European Journal of Clinical Nutrition 2022; van der Hee and Wells, Trends in Microbiology 2021
Modern lifestyle factors, including diets low in dietary fiber, results in a loss of gut microbial diversity linked to decreased levels of key bacterial metabolites and impaired intestinal barrier function.
Iweala and Nagler, Annual Reviews Immunology 2019; Vijay and Valdes, European Journal of Clinical Nutrition 2022; van der Hee and Wells, Trends in Microbiology 2021
Hypothesis: directly deliver bacterial metabolites
Utilize butyrate to correct impaired intestinal barrier function
Utilize butyrate to correct impaired intestinal barrier function
|
In preclinical models, butyrate-producing bacteria in the Clostridia class protect against intestinal inflammation
Butyrate induces IL-22, a barrier protective cytokine
Butyrate supports:
|
Probiotic solution
Support the gut microbiome by supplementing with CLB101™, a butyrate-producing commensal bacterial strain
Support the gut microbiome by supplementing with CLB101™, a butyrate-producing commensal bacterial strain
Therapeutic solution: Proprietary, oral, targeted metabolite delivery platform
CLB-004 enables butyrate to achieve its maximum therapeutic potential
CLB-004 enables butyrate to achieve its maximum therapeutic potential
